Sign in
Catch up on
Cancer Research
i
Cancer

Re-educating Macrophages to Combat Cancer

By Guest Author Luis Felipe Campesato inCancer |
Score: 2.00 / 24.9

With the recent progress in the field of immuno-oncology, harnessing the power of the immune system to fight cancer has become one of the pillars of cancer care. However, there is still much to be done, given that only a subset of patients are responsive to a new class of drugs called immune checkpoint inhibitors (ICI). A better understanding of the cancer immune biology and the repressive mechanisms existent in the tumor microenvironment will certainly provide new clues on how to effectively target tumors in a more comprehensive and tailored way. Among the immune cells populating solid tumors, myeloid cells  represent a large part and are known to play important tumor-promoting roles by their immunosuppressive effects on T-cell activation and promotion of tumor growth and metastasis. Previous studies have shown that the presence of myeloid cells, such as tumor-infiltrating neutrophils, macrophages and myeloid-derived suppressor cells (MDSCs) is associated with poor prognosis and ICI resistance in patients with various tumor types. Nevertheless, given their highly plastic phenotype, myeloid cells are able to exert a dual role on tumor growth depending on the local tissue environment. For instance, macrophages undergo a series of functional reprogramming depending on the stimuli they receive, as described by two different polarization states, M1 and M2. M1 macrophages represent pro-inflammatory cells that are able to mediate resistance to pathogens and promote antitumor immunity, while M2 macrophages are characterized by their tissue-remodeling, immune regulatory and tumor-promoting activity (Figure 1).

Figure 1: Schematic illustrating two of the possible polarization pathways of macrophages (Image credit: Luis Felipe Campesato, MSKCC).

With that, one of the most promising avenues of immuno-oncology research is figuring out how to skew the activation of myeloid cells from an immunosuppressive state towards a pro-inflammatory, antitumor phenotype in order to facilitate ICI response. Two recent publications in Nature by De Henau and collaborators and Kaneda and collaborators have described the role of a signaling protein called PI3K gamma (PI3Kγ)  as a key molecular switch that controls the immunosuppressive state of myeloid cells. These studies show that this pathway is highly active in suppressive myeloid cells and that its selective inactivation promotes a functional switch in myeloid cells, leading to an immunostimulatory transcriptional program that restores T-cell activation and cytotoxicity. Importantly, De Henau and collaborators showed that PI3Kγ inhibition only works on myeloid-enriched tumors and that it synergizes with ICB therapy (anti-PD-1 and anti-CTLA-4) to promote tumor regression and increased survival in mouse models of cancer. These findings introduce opportunities for new, more tailored combination therapies based on the patient's tumor-immune landscape.

This is certainly good news for cancer patients, and it is important to point out that the use of a PI3Kγ inhibitor is currently being tested in a Phase I clinical trial (clinicaltrials.gov identifier NCT02637531). These studies represent great examples of a successful bench to bedside research enterprise. Hopefully, there will be many more to come in the years ahead.


Further reading on this topic:

Sica A and Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas Journal of Clinical Investigation 122: 787-795


Did you like this article?
Communicating science in an appealing manner matters to our scientists, and if you would like to show your appreciation of their commitment, please feel free to beef up our Author of the Month award.

Other Articles by This Author

Further Articles in Cancer

Responses

This work is distributed under a Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA 4.0). The use, distribution and reproduction in other forums is permitted, provided the original author(s) and Capeia are credited, and a CC BY-SA license is applied. Images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material.